Quick Answer
enVVeno Medical Corp reported Stockholders Equity of $27.13 million for the year ending 2025.
- enVVeno Medical Corp showed a decrease of -35.6% in Stockholders Equity from 2024 to 2025.
- This data is from enVVeno Medical Corp's annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $3.54 million | Q1 2019: $2.87 million | Q2 2019: $4.65 million | Q3 2019: $3.08 million | Q1 2020: -$14.6 thousand | Q2 2020: $369.4 thousand | Q3 2020: $4.79 million | Q1 2021: $43.01 million | Q2 2021: $40.87 million | Q3 2021: $58.06 million | Q1 2022: $51.32 million | Q2 2022: $46.56 million | Q3 2022: $42.67 million | Q1 2023: $34.13 million | Q2 2023: $28.81 million | Q3 2023: $24.92 million | Q1 2024: $42.37 million | Q2 2024: $38.42 million | Q3 2024: $47.37 million | Q1 2025: $38.31 million | Q2 2025: $33.06 million | Q3 2025: $29.45 million.
- Over the full 10 years of available data (2016 to 2025), enVVeno Medical Corp's Stockholders Equity has grown by 743.0%.
- Historical annual values: Fiscal year 2025: $27.13 million | Fiscal year 2024: $42.16 million | Fiscal year 2023: $46.20 million | Fiscal year 2022: $38.73 million | Fiscal year 2021: $54.40 million | Fiscal year 2020: $7.10 million | Fiscal year 2019: $989.9 thousand | Fiscal year 2018: $2.04 million | Fiscal year 2017: -$11.13 million | Fiscal year 2016: -$4.22 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: